On Dec. 14, 2020, Pfizer and BioNTech announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany.

The study results demonstrated that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity. The results were published on the preprint server MedRxiv. It was authorized for emergency use for individuals 16 years of age and older in several countries around the world.